{"classes":[{"categories":[{"measurements":[{"comment":"N/A = not estimable","groupId":"OG000","spread":"NA","value":"366"},{"groupId":"OG001","spread":"24.3","value":"938"},{"groupId":"OG002","spread":"62.9","value":"1460"},{"groupId":"OG003","spread":"46.5","value":"7470"},{"groupId":"OG004","spread":"81.8","value":"4070"},{"groupId":"OG005","spread":"141.7","value":"5140"},{"groupId":"OG006","spread":"57.4","value":"8180"},{"groupId":"OG007","spread":"111.7","value":"9210"},{"groupId":"OG008","spread":"127.3","value":"7870"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"14"},{"groupId":"OG005","value":"10"},{"groupId":"OG006","value":"10"},{"groupId":"OG007","value":"5"},{"groupId":"OG008","value":"252"}],"units":"Participants"}],"description":"The AUC from time zero to the last quantifiable concentration point (Tlast). Blood samples for PK analysis of LDK378 were collected during the study from patients receiving LDK378.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants receiving 50 mg of LDK378","id":"OG000","title":"LDK378 50 mg"},{"description":"Participants receiving 100 mg of LDK378","id":"OG001","title":"LDK378 100 mg"},{"description":"Participants receiving 200 mg of LDK378","id":"OG002","title":"LDK378 200 mg"},{"description":"Participants receiving 300 mg of LDK378","id":"OG003","title":"LDK378 300 mg"},{"description":"Participants receiving 400 mg of LDK378","id":"OG004","title":"LDK378 400 mg"},{"description":"Participants receiving 500 mg of LDK378","id":"OG005","title":"LDK378 500 mg"},{"description":"Participants receiving 600 mg of LDK378","id":"OG006","title":"LDK378 600 mg"},{"description":"Participants receiving 700 mg of LDK378","id":"OG007","title":"LDK378 700 mg"},{"description":"Participants receiving 750 mg of LDK378.","id":"OG008","title":"LDK378 750 mg"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Pharmacokinetic Analysis Set (PAS) consisted of all patients (including NSCLC and non-NSCLC) who received at least 1 dose of LDK378 \\& had at least 1 evaluable PK sample","reportingStatus":"POSTED","timeFrame":"PK run-in of Dose Escalation phase","title":"Primary Pharmacokinetics (PK) Parameter: AUC0-last","type":"SECONDARY","unitOfMeasure":"ng*h/mL"}